Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.03 -0.05 (-4.63%)
At close: Oct 23, 2026 · 4:00 PM EDT

Chemomab Therapeutics (CMMB) Return on Sales [ROS] (2018 - 2019)

Updated

Analysis

Chemomab Therapeutics (CMMB) Return on Sales [ROS] (2018 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 24.35%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 37.86%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 20.57%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -133.21%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 28.37%
10 Chemomab Therapeutics 7.41 Mn -27.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 31.29%
Sep 30, 2018 4,175.00%
API Access

Chemomab Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CMMB&period=max&api_key=YOUR_API_KEY